Nilotinib Viatris

Nilotinib, the active ingredient in Nilotinib Viatris, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy used in hematologic malignancies that involve the BCR‑ABL fusion protein.

- Chronic myeloid leukemia (CML): Reduces leukemic cell proliferation and helps achieve hematologic and cytogenetic remission. - Accelerated phase CML: Controls disease progression and improves overall survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to remission when incorporated into combination regimens.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools often occurring early in therapy. - Rash: maculopapular skin eruptions. - Elevated liver enzymes: transient increases in ALT/AST. - Fatigue: generalized tiredness without clear cause.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion or ischemic heart disease. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Severe hepatotoxicity: marked elevation of liver enzymes with possible jaundice. - QT interval prolongation: potential for arrhythmias requiring ECG monitoring.

Patients should be monitored for specific safety concerns before and during treatment.

- Cardiac assessment: evaluate baseline cardiovascular risk and monitor for ischemic events. - Hepatic function: check liver enzymes regularly and adjust therapy if significant elevation occurs. - Electrolyte balance: maintain normal potassium and magnesium levels to reduce QT prolongation risk. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nilotinib may interact with several drug classes, affecting its concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure and toxicity. - Proton pump inhibitors: can reduce nilotinib absorption, compromising efficacy. - Anticoagulants (e.g., warfarin): heightened risk of bleeding due to altered metabolism.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib levels, reducing effectiveness. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy; consider dose adjustment. - Antacids containing aluminum or magnesium: may affect nilotinib bioavailability; separate dosing times.